+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

  • ID: 4282126
  • SWOT Analysis
  • June 2020
  • 49 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Celgene Corp
  • Daiichi Sankyo Co Ltd
  • Eisai Inc
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • MORE
Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. Its lead product candidate tazemetostat is a first-in-class EZH2 inhibitor finds application in hematological malignancies and solid tumors as a monotherapy and combination therapy in relapsed or refractory non-Hodgkin lymphoma. The company’s pipeline product candidates include G9a Inhibitor, PRMT 5 Inhibitor (GSK3326595), PRMT 1 Inhibitor (GSK3368715) and Pinometostat. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

May 04, 2020: Epizyme reports business progress and first quarter 2020 financial results
Mar 20, 2020: Epizyme appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
Feb 24, 2020: Epizyme provides business update and reports fourth quarter and full year 2019 financial results
Oct 30, 2019: Epizyme announces pipeline updates and third quarter 2019 results
Sep 04, 2019: Epizyme announces board of director appointments to support continued evolution and growth

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celgene Corp
  • Daiichi Sankyo Co Ltd
  • Eisai Inc
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • MORE
Section 1 - About the Company
  • Epizyme Inc - Key Facts
  • Epizyme Inc - Key Employees
  • Epizyme Inc - Key Employee Biographies
  • Epizyme Inc - Major Products and Services
  • Epizyme Inc - History
  • Epizyme Inc - Company Statement
  • Epizyme Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Epizyme Inc - Business Description
  • Epizyme Inc - Corporate Strategy
  • Epizyme Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Epizyme Inc - Strengths
  • Epizyme Inc - Weaknesses
  • Epizyme Inc - Opportunities
  • Epizyme Inc - Threats
  • Epizyme Inc - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Epizyme Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • May 04, 2020: Epizyme reports business progress and first quarter 2020 financial results
  • Mar 20, 2020: Epizyme appoints Jeffery Kutok, M.D., Ph.D., as Chief Scientific Officer
  • Feb 24, 2020: Epizyme provides business update and reports fourth quarter and full year 2019 financial results
  • Oct 30, 2019: Epizyme announces pipeline updates and third quarter 2019 results
  • Sep 04, 2019: Epizyme announces board of director appointments to support continued evolution and growth
  • Aug 09, 2019: Epizyme reports business progress and second quarter 2019 results
  • Jul 22, 2019: Epizyme strengthens leadership team with appointment of Paolo Tombesi as chief financial officer
  • May 06, 2019: Epizyme provides business update and reports first quarter 2019 financial results
  • Feb 26, 2019: Epizyme provides business update and reports fourth quarter and full year 2018 financial results
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact
  • Disclaimer
List of Tables
  • Epizyme Inc, Key Facts
  • Epizyme Inc, Key Employees
  • Epizyme Inc, Key Employee Biographies
  • Epizyme Inc, Major Products and Services
  • Epizyme Inc, History
  • Epizyme Inc, Subsidiaries
  • Epizyme Inc, Key Competitors
  • Epizyme Inc, Ratios based on current share price
  • Epizyme Inc, Annual Ratios
  • Epizyme Inc, Annual Ratios (Cont...1)
  • Epizyme Inc, Interim Ratios
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Epizyme Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Epizyme Inc, Performance Chart (2015 - 2019)
  • Epizyme Inc, Ratio Charts
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novartis AG
  • Constellation Pharmaceuticals Inc
  • Celgene Corp
  • Eisai Inc
  • Daiichi Sankyo Co Ltd
  • Merck & Co Inc
  • Takeda Pharmaceutical Co Ltd
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll